August 10, 2022

SPRC PROFILE

SciSparc Ltd LogoOUR NEW PROFILE IS:   (NASDAQ: SPRC)

CHECK OUT THE INVESTOR PRESENTATION HERE

SCISPARC LTD. ANNOUNCES INITIAL POSITIVE RESULTS FOR THE COCAINE ADDICTION TREATMENT OF CLEARMIND MEDICINE INC

__________________________

Hello Everyone,

I hope that you were able to watch out last Nasdaq profile.  It exploded out of the gate and ran to highs of 19% from the opening trade.

We have another exciting Nasdaq company that we want you to pay attention to for today’s session.

Pull up SPRC immediately.

SciSparc’s Board of Directors Provides Strategic Decision

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that the Company’s board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value.

Potential strategic transactions to be explored and evaluated during the review process may include additional investments in innovative companies, acquisitions, a strategic partnership with one or more parties, or the licensing of one or more of the Company’s proprietary technologies or indications. If any such transaction results in equity consideration, the Company may consider making dividend in kind distributions, subject to applicable law and regulations, to its shareholders.

Pending any decision to undertake any such strategic transaction, the Company will continue its development activities in accordance with its existing business strategy.

“Our cash position provides us the opportunity to carefully consider a range of potential strategic alternatives designed to maximize shareholder value,” said Oz Adler, SciSparc’s Chief Executive Officer. “As we assess potential external strategic alternatives, we continue to seek to create value through the development of unique clinical-stage treatments for the central nervous system, including Alzheimer’s disease, Tourette syndrome and more. We plan to continue our trials according to the FDA guidelines and explore our new path with psychedelic pharmaceutical treatments.”

ABOUT SCISPARC

SciSparc’s proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.

Our primary platforms focus on the endocannabinoid system. The SciSparc pipeline composes both FDA – approved, and New Chemical Entities (NCEs) which we believe have strong potential to be indicated for targeted conditions, with no existing or sufficiently effective therapies.

Enhancing existing compounds with our proprietary technologies, we have developed novel therapies that demonstrate in clinical trials heightened bioavailability, significantly improved efficacy, lower dosage requirements, better safety profiles and a reduction in side effects.

CATALYSTS

  • Proprietary Technology with cutting-edge drug combinations addressing large global unmet medical needs
  • Two Phase 2 Assets addressing multi-billion markets and a Pending Phase 3* Clinical Trial
  • Attractive valuation & well capitalized to execute 2022 objectives
  • Key strategic partners, including leading universities, medical centers and KOLs
  • Preparing to file Investigational New Drug (IND) application in pain
  • Top-line pre-clinical SE study results in Status Epilepticus expected in the second half of 2022

2021- 2022 PRE-CLINICAL & CLINICAL ACHIEVEMENTS

  • SCI–110 for Alzheimer’s disease and Agitation – Recruited first patient for the Company’s Phase IIa
  • Entered an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel- Aviv Sourasky Medical Center, in Tel-Aviv, Israel, to further the Company’s Phase IIb clinical study for SCI-110 for patients suffering from Tourette Syndrome
  • Entered into agreement with The Sheba Fund for Health Services and Research, to perform a pre- clinicalstudyforthe evaluationoftheCompany’sSCI-210drugdevelopmentprogram,forthe treatment of Status Epilepticus (SE)
  • Received positive top-line results for the Company’s proprietary compound, SCI-160, in a controlled pre-clinical trial on Neuropathic and Post-operative pain

ROBUST IP PORTFOLIO

Repurposing previously approved compounds qualifies SciSparc to take advantage of the FDA’s 505 (b)(2) application protocol. This potentially means lower risk, and an expedited development timeline. The result is a robust pipeline of product candidates well positioned to create significant shareholder value into the future.

SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system. Currently, our drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain.

Our research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) and
products that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable us to generate immediate revenues for the company. augmenting FDA-approved natural and synthetic cannabinoids in combination with our proprietary compounds and technologies to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.

SCI-110, our proprietary drug candidate, containing Dronabinol (FDA approved synthetic form of THC), with the endocannabinoid palmitoylethanolamide (PEA).

Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events.

This product is being developed under the accelerated regulatory path of 505 (b)(2) application focused on augmenting FDA-approved natural and synthetic cannabinoids to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.

This approach qualifies us for access to the  FDA’s 505 (b)(2) regulatory strategy, created to facilitate the submission of novel drug candidates that meet specific criteria to the FDA for review. The 505 (b)(2) application provides us with several advantages as compared to a typical New Drug Application, including potential; lower risk and development costs, and a potentially expedited time to market.

Indications currently being investigated for treatment with SCI-110 include:

– Tourette Syndrome- (TS)
– Obstructive Sleep Apnea (OSA)
– Alzheimer’s Disease and Agitation

NEWS

TUE JUN 7TH, 2022

  • GlobeNewswire8:30 AM

    SCISPARC LTD. ANNOUNCES INITIAL POSITIVE RESULTS FOR THE COCAINE ADDICTION TREATMENT OF CLEARMIND MEDICINE INC.

THU JUN 2ND, 2022

  • GlobeNewswire8:30 AM

    SCISPARC LTD. AND CLEARMIND MEDICINE INC. COLLABORATION YIELDS ANOTHER PATENT APPLICATION FOR THEIR PROPRIETARY PSYCHEDELIC COMBINATION TO TREAT COCAINE ADDICTION

WED JUN 1ST, 2022

  • GlobeNewswire4:07 PM

    SCISPARC LTD. ANNOUNCES CLOSING OF $10 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

TUE MAY 31ST, 2022

  • GlobeNewswire8:30 AM

    SCISPARC TO COLLABORATE WITH POLYRIZON FOR BRAIN TARGETING USING INTRANASAL HYDROGEL SYSTEMS

FRI MAY 27TH, 2022

  • GlobeNewswire9:15 AM

    SCISPARC ANNOUNCES PRICING OF $10 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

THU MAY 26TH, 2022

  • GlobeNewswire8:30 AM

    SCISPARC ANNOUNCES ETHICS COMMITTEE APPROVAL TO CONDUCT A PHASE IIB TRIAL IN TOURETTE SYNDROME

TUE MAY 24TH, 2022

  • GlobeNewswire8:30 AM

    SCISPARC AND CLEARMIND MEDICINE INC. COLLABORATION YIELDS POSITIVE RESULTS FOR ITS PSYCHEDELIC COMBINATION TREATMENT

TUE MAY 10TH, 2022

  • GlobeNewswire8:30 AM

    CLEARMIND MEDICINE INC. AND SCISPARC LTD., COLLABORATION YIELDS NEW PROVISIONAL PATENT APPLICATION FOR PSYCHEDELIC COMBINATION TREATMENT FOR BINGE BEHAVIORS

  • GlobeNewswire8:30 AM

    SCISPARC LTD. AND CLEARMIND MEDICINE INC. COLLABORATION YIELDS NEW PATENT APPLICATION FOR PSYCHEDELIC COMBINATION TREATMENT FOR BINGE BEHAVIORS

MON MAY 2ND, 2022

  • GlobeNewswire8:41 AM

    SCISPARC FILES ANNUAL REPORT FOR YEAR ENDED DECEMBER 31, 2021 AND PROVIDES CORPORATE UPDATE

THU MAR 31ST, 2022

  • GlobeNewswire9:30 AM

    SCISPARC ANNOUNCES CLOSING OF NEW JV TARGETING DISCOVERY OF POTENTIAL DRUGS FOR CANCERS AND INFECTIOUS DISEASES

WED MAR 30TH, 2022

  • GlobeNewswire8:30 AM

    PROF. AVI SCHROEDER JOINS SCISPARC’S SCIENTIFIC ADVISORY BOARD TO SUPPORT THE COMPANY’S DEVELOPMENT OF SCI-160 FOR TREATING PAIN

THU MAR 17TH, 2022

  • PR Newswire8:00 AM

    SCISPARC ANNOUNCES POSITIVE RESULTS FROM PSYCHEDELIC-BASED PRE-CLINICAL TRIAL

THU MAR 10TH, 2022

  • PR Newswire8:30 AM

    SCISPARC LAUNCHES NEW JV TARGETING DISCOVERY OF POTENTIAL DRUGS FOR CANCERS AND INFECTIOUS DISEASES

TUE MAR 8TH, 2022

  • PR Newswire8:30 AM

    SCISPARC ENTERS COLLABORATION FOR THE DEVELOPMENT OF INNOVATIVE PSYCHEDELIC-BASED PHARMACEUTICALS

TUE FEB 22ND, 2022

  • PR Newswire9:00 AM

    SCISPARC TO PRESENT AT AEGIS VIRTUAL CONFERENCE

THU JAN 27TH, 2022

  • PR Newswire8:30 AM

    SCISPARC PRESENTS NEW LEADERSHIP LINEUP

TUE JAN 18TH, 2022

  • PR Newswire8:02 AM

    SCISPARC ADVANCES ITS PHASE IIB CLINICAL TRIAL IN PATIENTS WITH TOURETTE SYNDROME WITH ITS PROPRIETARY DRUG CANDIDATE SCI-110

TUE JAN 11TH, 2022

  • PR Newswire8:30 AM

    SCISPARC EXPLORING PSYCHEDELICS AS POSSIBLE AVENUE TO EXPAND ITS IP PORTFOLIO

THU JAN 6TH, 2022

  • PR Newswire9:00 AM

    SCISPARC ANNOUNCES RECRUITMENT OF FIRST PATIENT FOR ITS PHASE IIA CLINICAL TRIAL IN ALZHEIMER’S DISEASE

TUE JAN 4TH, 2022

  • PR Newswire8:44 AM

    SCISPARC ISSUED U.S. PATENT FOR ITS CORE TECHNOLOGY THAT TREATS CENTRAL NERVOUS SYSTEMS DISORDERS

    ___________________________

TOP MANAGEMENT

AMITAY WEISS

Chairman

Mr. Weiss has served as our Chief Executive Officer between August 2020 and January 2021 and on our Board of Directors since August 2020. He is founder and Chief Executive Officer of Amitay Weiss Management Ltd. Prior to forming his company, he held several positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He currently chairs and serves as director on the boards of several public companies. Mr. Weiss earned his B.A. in Economics from New England College, and his M.B.A. and LL.B from Ono Academic College in Israel – a branch of the University of Manchester.

OZ ADLER, CPA

Chief Executive Officer and Chief Financial Officer

Mr. Adler joined the Company in September 2017, and since April 2018 serves as the Company Chief Financial Officer .Mr. Adler has a wide variety of managerial, financial, tax and accounting experience. Prior to joining the Company, Mr. Adler was employed as a CPA at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. He currently chairs and serves as director on the boards of several private and public companies. Mr. Adler holds a B.A. in Accounting and Business Management from The College of Management, Israel.

ADI ZULOFF-SHANI,  PHD.

Chief Technologies Officer.

Dr. Zuloff-Shani joined the Company in February 2016, bringing more than 20 years of experience as a research and development executive in the bio-tech industry and launching start-ups in the healthcare industry. Dr. Zuloff-Shani brought 2 products from bench to market and is currently leading the development of several pharmaceutical products designated to the U.S., EU and Israeli markets.  Prior to joining us, Dr. Zuloff-Shani served as Vice President Development at Macrocure Ltd. (Nasdaq: MCUR) where she led all research and development activities. Dr. Zuloff-Shani earned her Ph.D. in Human Biology and Immunology from Bar-Ilan University, Israel.

Sincerely,

The Viral Stocks Team

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF GLOBAL COIN MEDIA, LLC.  HEREIN REFERRED TO AS GCM, LLC.  WE ARE A NEVADA COMPANY. OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  WE  HAVE BEEN COMPENSATED A FEE OF TWENTY SEVEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, AWARENESS CONSULTING NETWORK, LLC FOR A ONE DAY SPRC AWARENESS CAMPAIGN.  NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: GCMLLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD GCM, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. GCMLLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND GCM, LLCMAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD GCM, LLC.  STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.GCM, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. GCM, LLCDOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND GCM, LLCFURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION,GCM, LLCHAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, GCM, LLCAND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. GCM, LLCIS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS GCM, LLCRESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. GCM, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]